RAF dimerization and phosphorylation downstream of oncogenic RAS and RAF mutations is associated with increased MAP2K and MAPK phosphorylation (Wan et al, 2004; Garnett et al, 2005; reviewed in Holderfield et al, 2014). Although the interactions between oncogenic RAS or RAFs and downstream effectors hasn't been studied in detail, these disease pathways are presumed to recruit MAP2Ks and MAPKs in a scaffold-dependent manner similar to WT (reviewed in Matallanas et al, 2011).
McCormick, F, Deuker, MM, McMahon, M, Holderfield, M
Garnett, MJ, Barford, D, Paterson, H, Rana, S, Marais, R
Niculescu-Duvaz, D, Lee, S, Marais, R, Marshall, CJ, Barford, D, Jones, CM, Good, VM, Springer, CJ, Wan, PT, Garnett, MJ, Roe, SM
Romano, D, Matallanas, D, Rauch, J, Zebisch, A, Birtwistle, M, Kolch, W, von Kriegsheim, A
Gain of function of RAS mutants:GTP:p-RAF homo/heterodimer [plasma membrane]
© 2023 Reactome